Agios Pharma Inc v. Annora Pharma Pvt Ltd

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Agios Pharmaceuticals, Inc. (Delaware)
  • Defendant: Annora Pharma Private Limited (India); Hetero Labs Limited (India); and Hetero USA Inc. (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP
• Case Identification: 1:26-cv-00603, D. Del., 05/26/2026
• Venue Allegations: Venue is alleged to be proper as to Defendant Hetero USA Inc. because it is a Delaware corporation and therefore resides in the district. Venue is alleged as to the foreign defendants, Annora Pharma Private Limited and Hetero Labs Limited, on the basis that they are foreign corporations that may be sued in any judicial district.
• Core Dispute: Plaintiff alleges that Defendants' filing of an Abbreviated New Drug Application (ANDA) for a generic version of Plaintiff's Pyrukynd® (mitapivat) drug product constitutes an act of infringement of three U.S. patents.
• Technical Context: The lawsuit is in the field of pharmaceutical science, concerning a small-molecule activator of the pyruvate kinase (PK) enzyme for the treatment of hemolytic anemia associated with PK deficiency.
• Key Procedural History: This action arises under the Hatch-Waxman Act following Defendants' submission of ANDA No. 221270, seeking FDA approval to market a generic version of Pyrukynd®. Plaintiff was notified of the ANDA filing, which included a Paragraph IV certification challenging the asserted patents, via a notice letter dated April 16, 2026. This complaint was filed within the 45-day statutory window, triggering a potential 30-month stay of FDA approval for the ANDA.

Case Timeline

Date	Event
2015-06-11	'976 Patent Priority Date
2017-11-22	'652 Patent Priority Date
2019-06-14	'049 Patent Priority Date
2022-02-01	U.S. Patent No. 11,234,976 Issues
2022-02-22	U.S. Patent No. 11,254,652 Issues
2024-01-23	U.S. Patent No. 11,878,049 Issues
2026-04-16	Defendants send Paragraph IV Notice Letter
2026-05-26	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 11,234,976 - "Methods of Using Pyruvate Kinase Activators" (02/01/2022)

The Invention Explained

• Problem Addressed: The patent describes pyruvate kinase deficiency (PKD), a genetic disorder causing an enzyme defect in red blood cells that leads to chronic non-spherocytic hemolytic anemia (HNSHA) ʼ976 Patent, col. 1:15-25 This deficiency results in insufficient levels of adenosine triphosphate (ATP), which is critical for maintaining red blood cell integrity, leading to premature cell destruction and anemia ʼ976 Patent, col. 1:30-49
• The Patented Solution: The invention provides a method for treating PKD by orally administering a specific compound, N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide ("Compound 1"), which acts as an allosteric activator of the pyruvate kinase R (PKR) enzyme ʼ976 Patent, abstract ʼ976 Patent, col. 7:17-30 The claimed method specifies particular oral dosage ranges and frequencies to manage the condition ʼ976 Patent, claim 1
• Technical Importance: The invention provides a potential disease-modifying therapy for a rare disorder for which treatment options were previously limited to palliative care, such as blood transfusions and splenectomy ʼ976 Patent, col. 2:33-39

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶40
• Claim 1 recites:
  • A method for treating pyruvate kinase deficiency (PKD) in a subject.
  • The method comprises orally administering to the subject once or twice daily a dose of about 10 mg to about 60 mg, or about 60 mg to about 200 mg.
  • The dose is of Compound 1 (or a salt/hydrate thereof), or a pharmaceutical composition containing it.
  • Compound 1 is defined as N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide.

U.S. Patent No. 11,254,652 - "Crystalline Forms of N-(4-(4-(Cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide" (02/22/2022)

The Invention Explained

• Problem Addressed: The development of small-molecule drugs requires stable and consistent physical forms of the active pharmaceutical ingredient. The patent notes a need to develop alternative forms of the mitapivat compound to facilitate manufacturing, formulation, and storage stability ʼ652 Patent, col. 1:62-68
• The Patented Solution: The patent discloses specific crystalline salt forms of mitapivat, including a hemisulfate salt designated "crystalline form A" ʼ652 Patent, abstract This form is defined by a unique pattern of peaks in an X-ray powder diffraction (XRPD) analysis, which provides a distinct and reproducible solid-state structure ʼ652 Patent, col. 2:11-17 ʼ652 Patent, claim 1
• Technical Importance: A well-characterized, stable crystalline form is essential for ensuring consistent quality, bioavailability, and shelf-life in a commercial pharmaceutical product.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 Compl. ¶54
• Claim 1 recites:
  • A crystalline form of a compound having a specific chemical structure (mitapivat hemisulfate).
  • The crystalline form is specified as "crystalline form A."
  • Crystalline form A is characterized by x-ray powder diffraction peaks at specific 2θ angles (±0.2°): 9.9°, 15.8°, and 22.6°.

U.S. Patent No. 11,878,049 - "Mitapivat Therapy and Modulators of Cytochrome P450" (01/23/2024)

• Technology Synopsis: The patent addresses the fact that mitapivat is primarily metabolized by the cytochrome P450 3A4/5 (CYP3A4/5) enzymes ʼ049 Patent, col. 1:5-9 This creates a risk for drug-drug interactions when co-administered with other drugs that induce or inhibit these enzymes. The invention provides a method for treating hemolytic anemia by administering mitapivat in combination with a moderate inducer of CYP3A4/5, specifying particular mitapivat dosage regimens for such a scenario ʼ049 Patent, claim 1
• Asserted Claims: The complaint asserts at least independent claim 1 Compl. ¶67
• Accused Features: The infringement allegation is based on the use of Annora's Proposed ANDA Product as will be directed by its proposed label, which is alleged to cover the administration of mitapivat with a moderate inducer of CYP3A4/5 Compl. ¶¶67-69

III. The Accused Instrumentality

Product Identification

"Annora's Proposed ANDA Product," which is a generic version of Pyrukynd® (mitapivat) submitted for FDA approval under ANDA No. 221270 Compl. ¶1

Functionality and Market Context

The accused product is a set of tablets in 5, 20, and 50 mg strengths containing mitapivat (present as mitapivat sulfate) as the active ingredient Compl. ¶1 Compl. ¶36 It is intended to be a bioequivalent substitute for the brand-name drug Pyrukynd® and will be marketed for the same indication: treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency Compl. ¶1 The complaint alleges that the product's proposed label will instruct healthcare professionals to prescribe and administer the drug in a manner that infringes the asserted patents Compl. ¶38

IV. Analysis of Infringement Allegations

11,234,976 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for treating pyruvate kinase deficiency (PKD) in a subject in need thereof,	Defendants' proposed product is intended for treating PKD, and the proposed label will instruct its use for this purpose Compl. ¶1	¶40; ¶42	col. 1:15-18
comprising orally administering to the subject once or twice daily a dose of about 10 mg to about 60 mg or about 60 mg to about 200 mg	The proposed product is supplied in tablet form for oral administration, and the proposed label will allegedly instruct once or twice daily dosing that falls within the claimed ranges Compl. ¶1 Compl. ¶40	¶40; ¶42	col. 7:17-20
of (1) Compound 1 or a pharmaceutically acceptable salt or hydrate thereof... wherein Compound 1 is N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide.	The active ingredient in Defendants' proposed product is mitapivat (Compound 1), present as mitapivat sulfate, which is a pharmaceutically acceptable salt Compl. ¶36 Compl. ¶40	¶36; ¶40	col. 7:21-26

• Identified Points of Contention:
  • Scope Questions: A central question will be one of induced infringement: does the language of the Defendants' proposed product label instruct or encourage physicians to administer the drug in a way that falls squarely within the dosage and frequency limitations of claim 1? The analysis may focus on whether the label mandates, or merely permits, an infringing use.
  • Technical Questions: The court may need to consider whether the "about" language in the dosage claims encompasses the specific dosing regimens that will be recommended in the Defendants' final approved label.

11,254,652 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A crystalline form of a compound having the formula: [structure provided]	The complaint alleges that the active ingredient in the proposed ANDA product is mitapivat, present as mitapivat sulfate, which corresponds to the chemical structure depicted Compl. ¶36 Compl. ¶54 The complaint provides a chemical structure of the hemisulfate salt form of the compound claimed in the '652 Patent Compl. ¶54	¶36; ¶54	col. 10:5-25
wherein the crystalline form is crystalline form A characterized by x-ray powder diffraction peaks at 2θ angles (±0.2°) 9.9°, 15.8°, and 22.6°.	On "information and belief," the complaint alleges that the proposed ANDA product contains or is a crystalline salt form covered by at least claim 1 Compl. ¶55	¶55	col. 9:30-33

• Identified Points of Contention:
  • Scope Questions: Practitioners may focus on whether the term "characterized by" requires the presence of only the three listed XRPD peaks, or if it implies a substantial similarity to the overall XRPD pattern of Form A as disclosed in the patent.
  • Technical Questions: A primary factual dispute will be whether the Defendants' generic product is, in fact, "crystalline form A." The complaint alleges this on "information and belief," but resolution will depend on expert analysis of the defendants' actual drug substance, likely through techniques like XRPD, once that evidence is produced in discovery.

V. Key Claim Terms for Construction

For U.S. Patent No. 11,234,976:

• The Term: "about" (in the context of dosage, e.g., "about 10 mg to about 60 mg")
• Context and Importance: The definition of "about" is critical for determining the literal scope of the claimed dosage ranges. Defendants may argue their proposed labeled dosing falls outside the claimed ranges, making the interpretation of this term central to the infringement analysis.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent uses "about" consistently when reciting dosage ranges in the claims and the specification, suggesting the patentee intended to cover minor, insubstantial variations from the stated numerical values ʼ976 Patent, claim 1 ʼ976 Patent, col. 7:17-20
  • Evidence for a Narrower Interpretation: The patent discloses clinical trial data with specific dose cohorts (e.g., 30 mg, 120 mg, 360 mg) ʼ976 Patent, Figs. 5-6 A party could argue that "about" should be interpreted narrowly, limited to the range of variability expected in standard clinical or manufacturing practice and not extending to entirely different dosing paradigms.

For U.S. Patent No. 11,254,652:

• The Term: "characterized by x-ray powder diffraction peaks at 2θ angles (±0.2°) 9.9°, 15.8°, and 22.6°"
• Context and Importance: This term defines the patented crystalline form. The core of the infringement case for this patent will turn on whether the defendant's product meets this definition. Practitioners may focus on this term because the dispute is likely to be a "battle of the experts" over interpreting analytical data.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim language uses "characterized by," not "consisting of" or "having peaks only at." This may support an interpretation that the presence of these three peaks is sufficient for infringement, even if the accused product's XRPD pattern contains additional or different peaks ʼ652 Patent, claim 1
  • Evidence for a Narrower Interpretation: The specification provides a more extensive list of 2θ peaks for Form A ʼ652 Patent, col. 9:46-54 and a full XRPD diffractogram ʼ652 Patent, Fig. 1 A party could argue that to be "characterized by" this pattern, an accused product must exhibit a substantial correspondence to this more complete "fingerprint," not just three selected peaks.

VI. Other Allegations

• Indirect Infringement: The complaint alleges Defendants will induce infringement of the method claims of the '976 and '049 patents. The basis for inducement is the allegation that Defendants' proposed product label will instruct and encourage healthcare professionals to administer the drug in a manner that directly infringes the claimed methods of use Compl. ¶49 Compl. ¶75 The complaint also alleges contributory infringement, stating the proposed product is especially made for the patented uses and is not suitable for substantial non-infringing use Compl. ¶50 Compl. ¶76
• Willful Infringement: The complaint does not contain an explicit count for willful infringement. However, it alleges facts that may support a future claim for enhanced damages by asserting that Defendants had pre-suit knowledge of the asserted patents because they are listed in the FDA's Orange Book for Pyrukynd® Compl. ¶48 Compl. ¶61 Compl. ¶74 The complaint also notes that Defendants filed a Paragraph IV certification, acknowledging the patents while asserting their invalidity or non-infringement Compl. ¶34

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of polymorphic identity: What will the evidence, once produced in discovery, show about the solid-state structure of the Defendants' mitapivat sulfate? Does it exhibit the specific X-ray diffraction peaks that characterize "crystalline form A" as claimed in the '652 patent, or does it constitute a distinct, non-infringing polymorph?
• A second key question will be one of label-driven inducement: For the method-of-use claims in the '976 and '049 patents, does the language of the Defendants' proposed product label actively instruct or encourage physicians to prescribe the generic drug in a way that directly practices every step of the claimed methods, including the specific dosage, frequency, and co-administration limitations?
• A third question concerns claim construction: How broadly will the court interpret the term "about" in the context of the dosage claims of the '976 patent? The outcome of this construction could be determinative of whether the dosing instructions on the accused product's label fall within the literal scope of the claims.